Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

J&J reaches $205 million settlement in Australian pelvic mesh class action

Published 09/12/2022, 12:58 AM
Updated 09/12/2022, 11:27 AM
© Reuters. FILE PHOTO: The Johnson & Johnson logo is displayed on a screen on the floor of the New York Stock Exchange (NYSE) in New York, U.S., May 29, 2019. REUTERS/Brendan McDermid/File Photo

By Jaskiran Singh

(Reuters) - Johnson & Johnson (NYSE:JNJ) (J&J) has reached a A$300 million ($204.90 million) settlement in two Australian class action suits filed by Shine Lawyers for selling defective pelvic mesh implants to Australian women, the law firm said on Monday.

The settlement, which Shine Lawyers said was the largest settlement in a product-liability class action in Australian history, follows multiple court proceedings involving more than 11,000 claimants, the pharmaceutical giant, and its subsidiary Ethicon.

Pelvic mesh manufacturers have faced thousands of lawsuits from women who said they suffered pain, urinary problems, bleeding, and other serious injuries from the implants. The total settlements for the companies have been more than $8 billion so far. (https://reut.rs/3DiXHT0)

J&J has also faced similar lawsuits in the United States, Canada, and Europe.

Earlier this year, a California court had ordered J&J to pay $302 million for concealing the risks of Ethicon's pelvic mesh products. (https://reut.rs/3xfAVYp)

Monday's settlement comes after an Australian federal court judge previously found that Ethicon had sold the implants — to treat urinary incontinence and pelvic organ prolapse — without warning women and surgeons about the risks, and had rushed the products to market before proper testing.

The company was ordered to pay $1.7 million to three Australian women in March 2020.

A second class action suit was then filed by Shine Lawyers in April 2021 on behalf of women who received their implants on or after July 4, 2017, and were not eligible to join the first class action, with allegations similar to the first one.

The A$300 million settlement remains subject to the Federal court's approval.

"Pending the Federal Court approval, we are pleased to reach a settlement that provides certainty and a path forward for eligible Australian patients," a Johnson & Johnson spokesperson said.

© Reuters. FILE PHOTO: The Johnson & Johnson logo is displayed on a screen on the floor of the New York Stock Exchange (NYSE) in New York, U.S., May 29, 2019. REUTERS/Brendan McDermid

In 2019, the U.S. Food and Drug Administration ordered all pelvic mesh makers to halt sales of the devices. (https://reut.rs/3RH2JwX)

($1 = 1.4641 Australian dollars)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.